Acute tumor lysis syndrome: Diagnosis and management

Yearbook of Intensive Care and Emergency Medicine 2009

Volumn , Issue , 2007, Pages 819-827

  Darmon, M ^a   Roumier, M ^a   Azoulay, E ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450141095     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-92278-2_75     Document Type: Chapter

References (40)

1. Yarpuzlu AA (2003) A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 333: 13-18
2. Metnitz PG, Krenn CG, Steltzer, et al (2002) Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 30: 2051-2058
3. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3-11
4. Davidson MB, Thakkar S, Hix JK, et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: 546-554
5. Kalemkerian GP, Darwish B, Varterasian ML (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103: 363-367
6. Altman A (2001) Acute tumor lysis syndrome. Semin Oncol 28:S3-8
7. Darmon M, Thiery G, Ciroldi M, et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33: 2488-2493
8. Montesinos P, Lorenzo I, Martin G, et al (2008) Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93: 67-74
9. Seegmiller JE, Laster L, Howell RR (1963) Biochemistry of uric acid and its relation to gout. N Engl J Med 268: 821-827
10. Seegmiller JE, Laster L, Howell RR (1963) Biochemistry of uric acid and its relation to gout. N Engl J Med 268: 764-773
11. Seegmiller JE, Laster L, Howell RR (1963) Biochemistry of uric acid and its relation to gout. N Engl J Med 268: 712-716
12. Conger JD, Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59: 786-793
13. Flombaum CD (2000) Metabolic emergencies in the cancer patient. Semin Oncol 27: 322-334
14. Hebert LA, Lemann J Jr, Petersen JR (1966) Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 45: 1886-1894
15. Munker R, Hill U, Jehn U, et al (1998) Renal complications in acute leukemias. Haematologica 83: 416-421
16. Coiffier B, Altman A, Pui CH, et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26: 2767-2778
17. Jeha S (2001) Tumor lysis syndrome. Semin Hematol 38:S4-8
18. Cohen LF, Balow JE, Magrath IT, et al (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 68: 486-491
19. Pui CH (2001) Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 38:S13-21
20. Goldman SC, Holcenberg JS, Finklestein JZ, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97: 2998-3003
21. Annemans L, Moeremans K, Lamotte M, et al (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 44: 77-83
22. Mato AR, Riccio BE, Qin L, et al (2006) A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 47: 877-883
23. Razis E, Arlin ZA, Ahmed T, et al (1994) Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 91: 171-174
24. Hussain K, Mazza JJ, Clouse LH (2003) Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol 72: 212-215
25. Fassas AB, Desikan KR, Siegel D, et al (1999) Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 105: 938-941
26. Terpos E, Politou M, Rahemtulla A (2004) Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 130: 623-625
27. Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 62: 247-250
28. Cany L, Fitoussi O, Boiron JM, et al (2002) Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 20:2212
29. Lee CC, Wu YH, Chung SH, et al (2006) Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist 11: 87-88
30. Cech P, Block JB, Cone LA, et al (1986) Tumor lysis syndrome after tamoxifen flare. N Engl J Med 315: 263-264
31. Stoves J, Richardson D, Patel H (2001) Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant 16: 188-189
32. Humphreys BD, Soiffer RJ, Magee CC (2005) Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 16: 151-161
33. Mehta RL, Pascual MT, Soroko S, et al (2002) Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 288: 2547-2553
34. Coiffier B, Mounier N, Bologna S, et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21: 4402-4406
35. Baeksgaard L, Sorensen JB (2003) Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol 51: 187-192
36. Haas M, Ohler L, Watzke H, et al (1999) The spectrum of acute renal failure in tumour lysis syndrome. Nephrol Dial Transplant 14: 776-779
37. Goldman SC (2003) Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 3: 429-433
38. Patte C, Sakiroglu C, Ansoborlo S, et al (2002) Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 13: 789-795
39. Annemans L, Moeremans K, Lamotte M, et al (2003) Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 11: 249-257
40. Browning LA, Kruse JA (2005) Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 39: 1932-1935